FDA approves Monjuvi for relapsed, refractory follicular lymphoma
The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Jun 23, 2025
0
14
Organic Chemicals: News and Research on Lenalidomide
MeSH tree: D02.241.223.805.810.400
Discovery of key mechanism could combat lenalidomide resistance in multiple myeloma
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance in multiple myeloma ...
Apr 10, 2025
0
19
Lower dexamethasone dose does not impair survival in multiple myeloma
For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.
Jan 24, 2025
0
17
Advanced cancer models could help personalize lymphoma treatments
Scientists at EPFL have developed "lymphomoids," a pioneering cancer model that preserves the structure and multicellular composition of lymphoma tumors in the lab. Lymphomoids offer an innovative way to test the efficacy ...
Dec 18, 2024
0
13
New CAR-T cells offer on-demand control for cancer treatment
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then switched off on demand with ...
Oct 22, 2024
0
78
Tolerable treatments lacking for higher-risk myelodysplastic syndromes
There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia & Lymphoma.
Oct 20, 2023
0
53
Immune system plays vital role in longer multiple myeloma remission, new study shows
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune system plays in determining ...
Sep 6, 2023
0
60
Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer
Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) ...
Sep 1, 2023
0
52
Genetic test can guide treatment for blood cancer to prevent relapse
Scientists have found a new way to predict which patients with the blood cancer myeloma will benefit the most from a treatment often used to help keep the disease from coming back after a stem cell transplant.
Mar 20, 2023
0
49
Immune system holds clues to patients with high-risk smoldering myeloma likely to benefit from treatment
For many patients with a condition that often precedes multiple myeloma, early treatment can slow or delay the progression to myeloma. In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes ...
Nov 14, 2022
0
263
